ReviewFrontiers in immunology2021
Natural Killer Cells in the Malignant Niche of Multiple Myeloma.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Trial
- Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.Frontiers in immunology · 2026Trial
- Network-Based Bioinformatics Reveal Microenvironment-Driven Cell-to-Cell Communication in the Progression of Multiple Myeloma.International journal of molecular sciences · 2026Article
- Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.Blood cancer discovery · 2026Article
- CyTOF profiling of bone marrow immune dynamics across myeloma stages.Oncoimmunology · 2025Article
- CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.Cell communication and signaling : CCS · 2025Review
- Molecular and immunological determinants of long-term survival in multiple myeloma.Blood advances · 2025Review
- Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies-Comparative Characterization of Current Protocols.International journal of molecular sciences · 2025Review
- Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.Experimental hematology & oncology · 2024Review
- Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.Blood advances · 2024Article
- Integrating p53-associated genes and infiltrating immune cell characterization as a prognostic biomarker in multiple myeloma.Heliyon · 2024Article
- Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.International journal of molecular sciences · 2023Article
- Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.Cancer medicine · 2023Review
- NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells.Cell death & disease · 2023Article
- Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications.Biomarker research · 2023Review
- Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.Biomolecules · 2023Review
- Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.Blood advances · 2023Article
- Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.Frontiers in oncology · 2023Review
- Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.International journal of molecular sciences · 2022Review
- Overexpression of VEGF in the MOPC 315 Plasmacytoma Induces Tumor Immunity in Mice.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies, including multiple myeloma (MM). Nonetheless, NK cells are subjected to a variety of cancer defense mechanisms, leading to impaired maturation, chemotaxis, target recognition, and killing. This review aims to summarize the available and most current knowledge about cancer-related impairment of NK cell function occurring in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.